SynthesisMolecular biology reports2012
Quantitative assessment of the effect of MTHFR polymorphisms on the risk of lung carcinoma.
Synthesis in Molecular biology reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Pooled it
- MTHFR C677T gene polymorphism and head and neck cancer risk: a meta-analysis based on 23 publications.Disease markers · 2015Pooled it
- Methylenetetrahydrofolate reductase 677TT genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis.Medical science monitor : international medical journal of experimental and clinical research · 2014Pooled it
- Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene Ala222Val and susceptibility to ovary cancer: a systematic review and meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.Yonsei medical journal · 2013Pooled it
- Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis.Molecular biology reports · 2013Pooled it
- Quantitative assessment of the association between MTHFR C677T polymorphism and colorectal cancer risk in East Asians.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012Pooled it
- MTHFR polymorphisms and ovarian cancer risk: a meta-analysis.Molecular biology reports · 2012Pooled it
- Pooled it
- Differential Oral Microbial Input Determines Two Microbiota Pneumo-Types Associated with Health Status.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published studies on the relationships between 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and lung cancer risk have been conflicting. To derive a more precise estimation of the relationship, a meta-analysis was performed. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between MTHFR C677T and A1298C polymorphisms and lung cancer risk. A total of 15 studies including 10,753 cases and 11,275 controls described C677T genotypes, among which 11 articles totalling 6,161 cases and 7,684 controls described A1298C genotypes, were also involved in this meta-analysis. Overall, no significantly elevated lung cancer risk was found in any genetic models when all studies were pooled. For C677T polymorphism: (TT vs. CC: OR = 1.17, 95% CI = 0.97-1.42; TC vs. CC: OR = 1.06, 95% CI = 0.94-1.20; dominant model: OR = 1.09, 95% CI = 0.96-1.24; and recessive model: OR = 1.08, 95% CI = 0.95-1.24); for A1298C polymorphism: (CC vs. AA: OR = 1.04, 95% CI = 0.91-1.19; AC vs. AA: OR = 0.98, 95% CI = 0.91-1.06; dominant model: OR = 0.99, 95% CI = 0.92-1.06; and recessive model: OR = 1.05, 95% CI = 0.92-1.20). In the subgroup analyses, the results showed that 677T varients could decrease lung cancer risk in female (OR = 0.63, 95% CI = 0.41-0.95, P-value = 0.03, 677CC as reference). No evidence of any associations of MTHFR A1298C polymorphism with lung cancer was found in overall or subgroup analyses. Our meta-analysis supports that the common polymorphisms of C677T and A1298C in MTHFR gene are not susceptibility gene for lung cancer from currently available evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.